CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and BAARN, the Netherlands, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients,

Company awarded ISO 27001 Accreditation for its Information Security Management System The internationally recognized certification is set by the International Organization for Standardization (ISO), in partnership with the International Electrotechnical Commission (IEC) Accreditation demonstrates

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real- world clinical and genetic data into actionable information for patients,

CENTOGENE expands its SARS-CoV-2 testing solution to Düsseldorf Airport after successfully launching walk-in COVID-19 test facilities at Frankfurt and Hamburg Airport Company’s PCR tests now available for passengers departing from or arriving at Düsseldorf Airport, as well as to the general public

CAMBRIDGE, Mass., and ROSTOCK, Germany & BERLIN, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical

CENTOGENE has opened an expanded sampling area, next to the existing Walk-In COVID-19 Testing Facility, allowing significant increases in COVID-19 testing sampling capacity Innovative digital solutions continue to support the fight against the novel coronavirus with a customer-friendly testing

Publication demonstrates genome sequencing as the optimal standard for genetic testing Study presents the largest cohort of its kind with over 1,000 index cases Genome sequencing minimizes stepwise testing, thereby accelerating diagnosis for rare disease patients CAMBRIDGE, Mass.

CENTOGENE has recently opened coronavirus walk-in test centers at Frankfurt and Hamburg Airport, two of Germany’s largest airports Over 97% of COVID-19 test reports were processed within 24 hours in August 2020 – offering security and peace of mind to travelers The combination of electronic

CAMBRIDGE, Mass. and ROSTOCK, Germany and HAMBURG, Germany and BERLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and

CENTOGENE expands its SARS-CoV-2 testing solution to Hamburg Airport after successfully launching the first walk-in COVID-19 test facility at Frankfurt Airport in June 2020 in cooperation with Lufthansa Company’s PCR tests now available for passengers departing from Hamburg, and returning to

CAMBRIDGE, Mass., and ROSTOCK and BERLIN, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies,

CENTOGENE expands ongoing development cooperation with Ministry of Health and Social Protection of the Population of Tajikistan (MoH) to now include COVID-19 testing The project supports access to testing materials and laboratory devices for SARS-CoV-2 testing – funded by the German Federal

The combination of real-life data sets in rare diseases with innovative big data/artificial intelligence/novel scientific computational knowledge will transform biomedical research, product development, and therapy. R eal-life data and I nnovative B ioinformatic A lgorithms (RIBA project) will

CENTOGENE announces test kits for the detection of SARS-CoV-2 virus RNA now available on Amazon in Germany ─ the first of its type offered on the online marketplace Offering includes delivery of a full, safe, and high-quality COVID-19 testing solution ─ significantly broadening access to the

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients,

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, today announced that its paper ‘Rapid Large-Scale COVID-19 Testing During Shortages’ has been published in Diagnostics

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical

CAMBRIDGE, Mass. and SANTA MONICA, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, and the OESIS Network Inc, an innovation network of more than 600 schools across the U.S., today announced a partnership for

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 02, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical

Lufthansa becomes first globally leading airline with a solution for safe and convenient international air travel during this pandemic Landmark exclusive cooperation offers testing for passengers departing from or arriving at Frankfurt airport starting immediately Innovative concept supports a safe

Cambridge, Mass. and ROSTOCK, Germany and BERLIN, June 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 15, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 08, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical

CAMBRIDGE, Mass. and BERLIN and ROSTOCK, Germany, May 15, 2020 (GLOBE NEWSWIRE) -- Centogene N.V (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical

CAMBRIDGE, Mass., USA, ROSTOCK, Germany and BERLIN, Germany, May 12, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 08, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies,

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 06, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies,

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN,, May 05, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies,

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 21, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies,

ROSTOCK, Germany and COLOGNE, Germany, April 17, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and the

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 16, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies,

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Germany, April 15, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Germany, March 18, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 17, 2020 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG) ─ The Company today announced that Dr. Dirk H. Ehlers, COO and President of its Clinical Diagnostics Division, has decided to step down from his role after the Annual General Meeting in

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 29, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies,

CAMBRIDGE, Mass. and ROSTOCK, Germany, Feb. 25, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today

State-of-the-art Biorepository in Rostock, Germany is the first CAP-accredited repository outside the U.S. CAMBRIDGE, Mass. and ROSTOCK, Germany, Feb. 12, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and